Theodore G. Karrison

Theodore G. Karrison

Auto-generated profile, based on publicly available information

Theodore G. Karrison

University of Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Oral Oncology
Verified
Journal Article
Closed access
MLMark W. Lingen
Mark W. Lingen
JKJohn R. Kalmar
John R. Kalmar
TKTheodore Karrison
Theodore Karrison
PSPaul M. Speight
Paul M. Speight

1 October 2003 in Controlled Clinical Trials
Verified
Journal Article
Closed access
TKTheodore G. Karrison
Theodore G. Karrison
DHDezheng Huo
Dezheng Huo
RCRick Chappell
Rick Chappell

1 September 2016 in The Stata Journal: Promoting communications on statistics and Stata
Verified
Journal Article
Closed access
TKTheodore G. Karrison
Theodore G. Karrison
The log-rank test is perhaps the most commonly used nonparametric method for comparing two survival curves and yields maximum power under proportional hazards alternatives. While the assumption of proportional hazards is often reasonable, it need not hold. Several authors have therefore developed versatile tests using combinations of weighted log-rank statistics that are more sensitive to nonproportional hazards. Fleming and Harrington (1991, Counting Processes and Survival Analysis, Wiley) consider the family of Gρ statistics and their supremum versions, while Lee (1996, Biometrics 52: 721-725) and Lee (2007, Computational Statistics and Data Analysis 51: 6557-6564) propose tests based on the more extended Gρ,γ family. In this article, I consider Zm = max(| Z1 |, |Z2|, | Z3|), where Z1, Z2, and Z3 are z statistics obtained from G0,0, G1,0, and G0,1 tests, respectively. G0,0 corresponds to the log-rank test, while G1,0 and G0,1 are more sensitive to early and late-difference alternatives. I conduct a simulation study to compare the performance of Zm with the log-rank test, the more optimally weighted test, and Lee's (2007) tests, under the null hypothesis, proportional hazards, early difference, and late-difference alternatives. Results indicate that the method based on Zm maintains the type I error rate, provides increased power relative to the log-rank test under early difference and late-difference alternatives, and entails only a small to moderate power loss compared with the more optimally chosen test. I apply the procedure to two datasets reported in the literature, both of which exhibit nonproportional hazards. Versatile tests such as Zm may be useful in clinical trial settings where there is concern that the treatment effect may not conform to the proportional hazards assumption. I also describe the syntax for a Stata command, verswlr, to implement the method.

2 May 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
DSDaniel Spratt
Daniel Spratt
VLVinnie Y.T. Liu
Vinnie Y.T. Liu
JMJeff Michalski
Jeff Michalski
EDElai Davicioni
Elai Davicioni
ABAlejandro Berlin
Alejandro Berlin
FFFelix Y. Feng
Felix Y. Feng
Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was -7%, compared with 21% for higher GC patients (P-interaction = .04). This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease.

1 January 2013 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
DGDaniel M Geynisman
Daniel M Geynisman
YZYuanyuan Zha
Yuanyuan Zha
RKRangesh Kunnavakkam
Rangesh Kunnavakkam
MAMebea Aklilu
Mebea Aklilu
Daniel VT CatenacciDaniel VT Catenacci
Daniel VT Catenacci
HKHedy L Kindler
Hedy L Kindler
Background: CEA is expressed in >90% of pancreatic cancers (PC) and may be an appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass tolerance. We conducted a pilot randomized phase I trial in PC patients to determine the peptide dose required to induce an optimal CD8(+) T cell response. Methods: Patients with a PS 0-1, HLA-A2+ and CEA-expressing, previously-treated PC were randomized to receive 10 mu g (arm A), 100 mu g (arm B) or 1000 mu g (arm C) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression. Results: Sixty-six patients were screened and 19 enrolled of whom 14 received at least 3 doses of the vaccine and thus evaluated for the primary immunologic endpoint. A median of 4 cycles (range 1-81) was delivered. Median and mean peak IFN-gamma T cell response by ELISPOT (spots per 10(4) CD8(+) cells, Arm A/B/C) was 11/52/271 (A vs. C, p = 0.028) for medians and 37/148/248 (A vs. C, p = 0.032) for means. T cell responses developed or increased in 20%/60%/100% of pts in Arms A/B/C. Seven of the 19 patients remain alive at a minimum 32 months from trial initiation, including three with unresectable disease. Conclusions: The T cell response in this randomized phase I trial was dose-dependent with the 1 mg CEA peptide dose eliciting the most robust T cell responses. A signal of clinical benefit was observed and no significant toxicity was noted. Further evaluation of 1 mg CEA peptide with stronger adjuvants, and/or combined with agents to overcome immune inhibitory pathways, may be warranted in PC pts.

15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMark Korpics
Mark Korpics
BOBenjamin E. Onderdonk
Benjamin E. Onderdonk
RDRebekah E. Dadey
Rebekah E. Dadey
JHJared H. Hara
Jared H. Hara
LKLilit Karapetyan
Lilit Karapetyan
JLJason Luke
Jason Luke
BACKGROUND. We previously demonstrated the safety of stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) in patients with advanced solid tumors. This phase I clinical trial was expanded to study the safety of partial tumor irradiation (partial-Rx). We assessed irradiated local failure (LF) and clinical outcomes with correlations to biomarkers including CD8+ T cell radiomics score (RS) and circulating cytokines. METHODS. Patients received SBRT to 2–4 metastases and pembrolizumab for up to 7 days after SBRT. Tumors measuring up to 65 cc received the full radiation dose (complete-Rx), whereas tumors measuring more than 65 cc received partial-Rx. Landmark analysis was used to assess the relationship between tumor response and overall survival (OS). Multivariable analysis was performed for RS and circulating cytokines. RESULTS. In the combined (expansion plus original) cohort, 97 patients (219 metastases) were analyzed and received SBRT+P. Forty-six (47%) patients received at least 1 partial-Rx treatment. There were 7 (7.2%)dose-limiting toxicities (DLTs). 1-year LF was 7.6% overall, and 13.3% and 5.4% for partial-Rx and complete-Rx tumors, respectively (HR 2.32, 95% CI 0.90–5.97, P = 0.08). The overall, unirradiated, and irradiated objective response rates were 22%, 12%, and 34%, respectively. Irradiated tumor response to SBRT+P was associated with prolonged OS; 1-year OS was 71% (responders), 42% (mixed-responders), and 0% (nonresponders) (P < 0.01). High-RS was significantly associated with improved LF, progression-free survival (PFS), and OS. Elevated circulating IL-8 was independently associated with inferior PFS and OS. CONCLUSION. SBRT+P is safe in patients with large, advanced solid tumors. Additional studies are warranted to assess noninferiority of complete versus partial irradiation of tumors in the setting of immunotherapy. TRIAL REGISTRATION. Clinicaltrials.gov NCT02608385 FUNDING. Merck Investigator Studies Program; Hillman Fellows for Innovative Cancer Research Program; NIH grants UM1CA186690-06, P50CA254865-01A1, P30CA047904-32, and R01DE031729-01A1.